Lactate

Cat. No.:	HY-B2227		
CAS No.:	50-21-5		
Molecular Formula:	$C_3H_6O_3$		
Molecular Weight:	90.08		
Target:	Endogenou	s Metabo	olite
Pathway:	Metabolic E	inzyme/P	rotease
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

®

MedChemExpress

SOLVENT & SOLUBILITY

In Vitro	0, 1	1110.12 mM; Need ultrasonic) .10.12 mM; Need ultrasonic)			
		Solvent Mass Concentration	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	11.1012 mL	55.5062 mL	111.0124 mL
	Stock Solutions	5 mM	2.2202 mL	11.1012 mL	22.2025 mL
		10 mM	1.1101 mL	5.5506 mL	11.1012 mL
	Please refer to the so	olubility information to select the ap	propriate solvent.		

BIOLOGICAL ACTIV	ТТҮ	
Description	residues lactylation. Lactate is a glyco	exylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine lysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. immune protective role of lactate in anti-tumor immunity ^{[1][2]} .
IC ₅₀ & Target	Human Endogenous Metabolite	
In Vitro	cell metabolism toward oxidative pho Lactate (20 mM; 24 h) shows an increa MCE has not independently confirmed Cell Proliferation Assay ^[1]	esults in a significant decrease in cell proliferation and migration, acting and switching sphorylation ^[1] . se in the protein and mRNA expression levels of MCT1 and HCAR1 ^[1] . I the accuracy of these methods. They are for reference only. melanoma 92.1 cells

Product Data Sheet

OH

OH

		1
	Concentration:	20 mM
	Incubation Time:	24, 48 h
	Result:	Inhibited cell proliferation and migration.
	Western Blot Analysis ^[1]	
	Cell Line:	Uveal melanoma cells
	Concentration:	20 mM
	Incubation Time:	24 h
	Result:	Showed an increase in the protein expression levels of MCT1 and HCAR1
	Western Blot Analysis ^[1]	
	Cell Line:	Uveal melanoma cells
	Concentration:	20 mM
	Incubation Time:	24 h
	Result:	Induced a significant increase in mRNA expression levels of SLC16A1 and HCAR1.
vo	inhibition in MC38 colon	g/kg; subcutaneous; daily from Day 8 to 30 days) shows CD8+ T cell-dependent tumor growth a cancer model ^[2] . ntly confirmed the accuracy of these methods. They are for reference only.
	Animal Model:	Female C57BL/6 mice with MC38 colon cancer cells ^[2]
	Dosage:	1.6 g/kg
	Administration:	Subcutaneous; daily from Day 8 to 30 days
	Result:	Significantly suppressed tumor growth.

CUSTOMER VALIDATION

- Cell Res. 2023 Jul 13.
- J Exp Clin Cancer Res. 2024 Mar 5;43(1):68.
- J Ginseng Res. 2023 Dec 27.

See more customer validations on <u>www.MedChemExpress.com</u>

REFERENCES

[1]. Lucia Longhitano, et al. Lactate Rewrites the Metabolic Reprogramming of Uveal Melanoma Cells and Induces Quiescence Phenotype. Int J Mol Sci. 2022 Dec 20;24(1):24.

[2]. Qiang Feng, et al. Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity. Nat Commun. 2022 Sep 6;13(1):4981.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA